FULC
Fulcrum Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$521.48M
P/E Ratio
—
EPS
$-1.18
Beta
3.27
52W High
$15.74
52W Low
$2.49
50-Day MA
$8.90
200-Day MA
$8.80
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined diseases in areas of high unmet medical need in the United States. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-56.10M |
| EBITDA | $-83.38M |
| Operating Margin | 0.00% |
| Return on Equity | -25.30% |
| Return on Assets | -16.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $5.24 |
| Price-to-Book | 1.53 |
| Price-to-Sales (TTM) | 5.46 |
| EV/Revenue | 117.4 |
| EV/EBITDA | -3.10 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $66.60M |
| Float | $43.65M |
| % Insiders | 3.86% |
| % Institutions | 101.55% |
Analyst Ratings
Consensus ($19.00 target)
1
Strong Buy6
Buy1
Hold1
Strong SellData last updated: 4/8/2026